Phaseline

Companies › Ambrx

Ambrx: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 5 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Anvatabart Opadotin (ARX788)
Tubulin inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent
Tubulin, ERBB2Phase 2HER2 Positive Metastatic Breast Cancer; Breast Neoplasms; HER2-positive, Metastatic Breast Cancer; HER2-positive Breast Cancer …Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04829604Anvatabart Opadotin (ARX788)Phase 2HER2 Positive Metastatic Breast CancerOncologyDec 2026
NCT04983121Anvatabart Opadotin (ARX788)Phase 2Breast NeoplasmsOncologyAug 2027
NCT06663748Anvatabart Opadotin (ARX788)Phase 2HER2-positive, Metastatic Breast CancerOncologyNov 2027
NCT05426486Anvatabart Opadotin (ARX788)Phase 2HER2-positive Breast CancerOncologyDec 2028
NCT06224673Anvatabart Opadotin (ARX788)Phase 2HER2 Low Breast CarcinomaOncologyNov 2029

Targets

Tubulin (1) ERBB2 (1)

Companies with the same targets

Roche Beijing Biotech Pfizer Sichuan Kelun-Biotech Biopharmaceutical Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical RemeGen Takeda AbbVie Criterium

Companies built like this

Partner Therapeutics CrystalGenomics STCube Convergent Therapeutics I-Mab Biopharma US

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.